Phapros Tbk PT

PEHA · JK · Healthcare / Drug Manufacturers - Specialty & Generic

274.00IDR+2.00 (+0.74%)

Price History

Full chart

Market Stats

Previous Close272.00

Open272.00

Day Range272.00 – 280.00

52-Week Range202.12 – 451.34

Volume106.90K

Market Cap235.20B

P/E (TTM)5.92

Forward P/E0.00

EPS47.31

Dividend Yield1.82%

Beta0.40

50-Day Avg283.44

200-Day Avg284.34

About

PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides ethical generic and branded products; and medical devices, as well as toll manufacturing. It also exports its products. The company was founded in 1954 and is headquartered in Jakarta Selatan, Indonesia. PT Phapros Tbk is a subsidiary of PT Kimia Farma Tbk.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMs. Intan Abdams Katoppo
Employees1.25K
HeadquartersMenara Rajawali Lantai 17, Jakarta Selatan, Indonesia, 12950, Indonesia
Websitehttps://www.phapros.co.id

Leadership

Ms. Intan Abdams KatoppoPresident Director
Mr. Ferdinand TroeduDirector of Finance, Risk Management & Human Resources
Mr. Erfan Rio PranantoGeneral Manager of Accounting
Mr. Maraja Jeson SiregarDirector of Marketing & Director
Mr. Riza EffendiHead of Internal Control Unit · b. 1969
Mr. Diah IstantriHead of Risk Management Department
Ms. Zahmilia AkbarCorporate Secretary · b. 1988

Financials

Income Statement

Currency: IDR	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	470.67B	529.75B	521.61B	578.14B	691.25B	816.13B	1.00T	1.02T	1.11T	980.56B	1.05T	1.17T	1.01T	744.69B	940.88B
Growth (%)	-	+12.55%	-1.54%	+10.84%	+19.56%	+18.07%	+22.79%	+2.08%	+8.06%	-11.30%	+7.23%	+11.13%	-13.21%	-26.57%	+26.34%
Cost of Revenue	183.97B	208.78B	200.49B	244.19B	302.82B	360.30B	436.89B	439.95B	495.94B	457.07B	531.91B	584.98B	514.36B	474.03B	437.50B
Gross Profit	286.70B	320.97B	321.12B	333.95B	388.43B	455.83B	565.24B	583.02B	609.48B	523.49B	519.53B	583.50B	499.77B	270.66B	503.38B
Gross Margin	60.91%	60.59%	61.56%	57.76%	56.19%	55.85%	56.40%	56.99%	55.14%	53.39%	49.41%	49.94%	49.28%	36.35%	53.50%
Operating Expense	202.12B	236.07B	254.85B	262.39B	295.59B	327.02B	377.84B	389.31B	416.82B	364.96B	427.43B	484.73B	428.45B	568.61B	416.64B
Operating Income	84.57B	84.90B	66.27B	71.57B	92.83B	128.81B	187.40B	193.71B	192.66B	158.53B	92.10B	98.77B	71.32B	-297.95B	86.74B
Operating Margin	17.97%	16.03%	12.71%	12.38%	13.43%	15.78%	18.70%	18.94%	17.43%	16.17%	8.76%	8.45%	7.03%	-40.01%	9.22%
EBITDA	96.24B	100.80B	68.82B	88.26B	115.36B	157.37B	206.60B	248.05B	234.34B	210.94B	148.33B	154.83B	120.77B	-282.91B	136.09B
EBITDA Margin	20.45%	19.03%	13.19%	15.27%	16.69%	19.28%	20.62%	24.25%	21.20%	21.51%	14.11%	13.25%	11.91%	-37.99%	14.46%
Net Income	64.70B	69.16B	42.11B	45.33B	63.01B	87.00B	125.27B	132.31B	102.03B	48.49B	11.07B	28.07B	5.96B	-285.07B	28.03B
Net Income Margin	13.75%	13.06%	8.07%	7.84%	9.12%	10.66%	12.50%	12.93%	9.23%	4.94%	1.05%	2.40%	0.59%	-38.28%	2.98%
R&D	-	-	-	-	9.11B	12.41B	15.13B	21.64B	20.73B	23.61B	24.89B	27.30B	30.41B	49.17B	26.55B
R&D as % of Total Revenue	-	-	-	-	1.32%	1.52%	1.51%	2.12%	1.88%	2.41%	2.37%	2.34%	3.00%	6.60%	2.82%
Interest Expense	2.01B	6.23B	6.85B	14.91B	16.47B	21.42B	17.86B	44.94B	62.60B	94.45B	79.76B	61.21B	64.95B	59.40B	49.21B
Interest Expense % of Total Revenue	0.43%	1.18%	1.31%	2.58%	2.38%	2.62%	1.78%	4.39%	5.66%	9.63%	7.59%	5.24%	6.40%	7.98%	5.23%

Balance Sheet

Currency: IDR	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	462.59B	558.64B	643.09B	638.09B	680.65B	883.29B	1.18T	1.87T	2.10T	1.92T	1.84T	1.81T	1.77T	1.43T	1.39T
Total Liabilities	123.42B	183.02B	251.69B	229.84B	230.93B	261.21B	474.55B	1.08T	1.28T	1.18T	1.10T	1.03T	995.56B	1.04T	959.70B
Total Equity	339.17B	367.24B	382.97B	408.25B	449.72B	622.08B	701.39B	769.93B	800.51B	719.65B	719.49B	751.05B	749.53B	379.75B	414.52B
Cash	20.54B	43.63B	27.52B	38.82B	55.52B	70.89B	147.05B	108.63B	106.57B	60.19B	94.35B	147.68B	65.84B	92.00B	120.98B
Total Debt	24.11B	67.43B	123.78B	120.50B	114.00B	108.63B	232.88B	830.58B	1.02T	922.84B	876.86B	843.48B	802.58B	746.29B	706.66B
Net Debt	3.57B	23.80B	96.25B	81.69B	58.48B	37.74B	85.83B	721.95B	909.32B	862.64B	782.51B	695.80B	736.74B	654.28B	585.68B

Cash Flow

Currency: IDR	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-27.22B	56.90B	19.50B	84.04B	70.09B	114.08B	102.03B	-75.91B	-2.48B	259.48B	189.92B	28.07B	-14.44B	141.28B	70.98B
Investing Cash Flow	-10.55B	-63.60B	-49.22B	-24.39B	-5.06B	-41.37B	-89.17B	-399.56B	-30.79B	-25.83B	-10.34B	-12.55B	-10.52B	-12.19B	-7.03B
Financing Cash Flow	-17.59B	29.79B	24.56B	-48.72B	-45.62B	-57.82B	63.13B	436.76B	32.05B	-279.83B	-145.24B	-107.27B	-53.83B	-103.17B	-35.26B
Capital Expenditure	9.05B	51.45B	50.01B	26.80B	11.33B	42.89B	89.17B	83.81B	32.28B	28.18B	13.32B	15.37B	13.42B	15.19B	5.98B
Free Cash Flow	-36.27B	5.45B	-30.50B	57.24B	58.76B	71.19B	12.86B	-159.71B	-34.76B	231.31B	176.61B	12.70B	-29.06B	126.08B	65.00B
Dividends Paid	29.18B	32.09B	26.68B	30.53B	22.65B	31.04B	43.25B	84.73B	90.66B	69.17B	19.51B	9.83B	12.92B	78.62M	8.56M
FCF to OCF	133.26%	9.58%	-156.43%	68.11%	83.84%	62.41%	12.60%	210.41%	1400.60%	89.14%	92.99%	45.24%	201.21%	89.25%	91.57%
Dividend Paid to FCF	-80.44%	588.38%	-87.47%	53.35%	38.54%	43.60%	336.35%	-53.05%	-260.83%	29.90%	11.05%	77.39%	-44.47%	0.06%	0.01%

Earnings

Report Date	Mar 31, 2019	Sep 18, 2019	Sep 30, 2019	Mar 31, 2020	Apr 1, 2020	Aug 15, 2020	Nov 15, 2020	Feb 15, 2021	May 15, 2021	Aug 15, 2021	Nov 15, 2021	Feb 15, 2022	May 15, 2022	Aug 15, 2022	Nov 15, 2022	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	6.05	50.79	14.57	50.05	-16.47	48.47	27.54	-1.81	8.52	3.89	0.55	0.23	6.67	6.59	7.12	13.04	5.61	3.61
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	After-hours	-	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	-	-	-

Key Statistics & Ratios

Market Cap235.20B

Enterprise Value791.76B

Trailing P/E5.92

Forward P/E0.00

Price / Sales0.24

Price / Book0.58

EPS47.31

Book Value495.30

Revenue (TTM)965.50B

Gross Profit (TTM)504.20B

EBITDA164.54B

Profit Margin4.24%

Operating Margin14.34%

Return on Equity9.59%

Return on Assets5.42%

Shares Outstanding840.00M

Shares Float274.87M

Beta0.40

Dividend Yield1.82%

Dividend Rate5.01

Payout Ratio10.44%

Dividends

20261×

5.01Jun 23, 2026

20231×

13.37Jun 19, 2023

20221×

7.91Jun 7, 2022

20211×

23.09Jun 8, 2021

20201×

85.03Jul 6, 2020

20191×

110.26Mar 25, 2019